Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Sedki M, Levy C.

Curr Gastroenterol Rep. 2018 Jun 9;20(7):29. doi: 10.1007/s11894-018-0635-8. Review.

PMID:
29886518
2.

New therapies target the toxic consequences of cholestatic liver disease.

Jansen PLM.

Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):277-285. doi: 10.1080/17474124.2018.1424538. Epub 2018 Jan 10. Review.

PMID:
29310470
3.

24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: A new "urso saga" on the horizon?

Chazouillères O.

J Hepatol. 2017 Sep;67(3):446-447. doi: 10.1016/j.jhep.2017.06.024. Epub 2017 Jul 1. No abstract available.

PMID:
28676324
4.

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.

Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group.

J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18.

5.

Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.

Halilbasic E, Steinacher D, Trauner M.

Dig Dis. 2017;35(3):288-292. doi: 10.1159/000454904. Epub 2017 Mar 1. Review.

PMID:
28249255
6.

NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.

Krones E, Eller K, Pollheimer MJ, Racedo S, Kirsch AH, Frauscher B, Wahlström A, Ståhlman M, Trauner M, Grahammer F, Huber TB, Wagner K, Rosenkranz AR, Marschall HU, Fickert P.

J Hepatol. 2017 Jul;67(1):110-119. doi: 10.1016/j.jhep.2017.02.019. Epub 2017 Feb 27.

PMID:
28242240
7.

Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.

Halilbasic E, Fuchs C, Hofer H, Paumgartner G, Trauner M.

Dig Dis. 2015;33 Suppl 2:149-63. doi: 10.1159/000440827. Epub 2015 Dec 7. Review.

PMID:
26641242
8.

Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.

Buko VU, Lukivskaya OY, Naruta EE, Belonovskaya EB, Tauschel HD.

J Clin Exp Hepatol. 2014 Dec;4(4):293-301. doi: 10.1016/j.jceh.2014.02.001. Epub 2014 Feb 21.

9.

Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.

Trauner M, Halilbasic E, Kazemi-Shirazi L, Kienbacher C, Staufer K, Traussnigg S, Hofer H.

Dig Dis. 2014;32(5):631-6. doi: 10.1159/000360517. Epub 2014 Jul 14. Review.

PMID:
25034298
10.

Bile acids in cholestasis: bad for the liver, not so good for the kidney.

Erlinger S.

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):392-4. doi: 10.1016/j.clinre.2014.03.003. Epub 2014 Apr 14.

PMID:
24726271
11.

SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.

García-Rodríguez JL, Barbier-Torres L, Fernández-Álvarez S, Gutiérrez-de Juan V, Monte MJ, Halilbasic E, Herranz D, Álvarez L, Aspichueta P, Marín JJ, Trauner M, Mato JM, Serrano M, Beraza N, Martínez-Chantar ML.

Hepatology. 2014 May;59(5):1972-83. doi: 10.1002/hep.26971. Epub 2014 Mar 31.

12.

Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice.

Fickert P, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, Halilbasic E, Yang M, Jaeschke H, Stokman G, Wells RG, Eller K, Rosenkranz AR, Eggertsen G, Wagner CA, Langner C, Denk H, Trauner M.

Hepatology. 2013 Dec;58(6):2056-69. doi: 10.1002/hep.26599. Epub 2013 Oct 15.

PMID:
23813550
13.

Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.

König J, Klatt S, Dilger K, Fromm MF.

Basic Clin Pharmacol Toxicol. 2012 Aug;111(2):81-6. doi: 10.1111/j.1742-7843.2012.00865.x. Epub 2012 Mar 9.

14.

Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.

Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Höfler G, Lass A, Zechner R, Trauner M.

Gastroenterology. 2012 Jan;142(1):140-151.e12. doi: 10.1053/j.gastro.2011.09.051. Epub 2011 Oct 14.

PMID:
22001865
15.

Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis.

Culver EL, Chapman RW.

Aliment Pharmacol Ther. 2011 Jun;33(12):1273-91. doi: 10.1111/j.1365-2036.2011.04658.x. Epub 2011 Apr 18. Review.

16.

Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.

Denk GU, Maitz S, Wimmer R, Rust C, Invernizzi P, Ferdinandusse S, Kulik W, Fuchsbichler A, Fickert P, Trauner M, Hofmann AF, Beuers U.

Hepatology. 2010 Nov;52(5):1758-68. doi: 10.1002/hep.23911.

PMID:
21038414
17.

The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.

Trottier J, El Husseini D, Perreault M, Pâquet S, Caron P, Bourassa S, Verreault M, Inaba TT, Poirier GG, Bélanger A, Guillemette C, Trauner M, Barbier O.

J Biol Chem. 2010 Jan 8;285(2):1113-21. doi: 10.1074/jbc.M109.073908. Epub 2009 Nov 4.

18.

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M.

Hepatology. 2009 Jun;49(6):1972-81. doi: 10.1002/hep.22891.

19.

Sclerosing cholangitis.

Maggs JR, Chapman RW.

Curr Opin Gastroenterol. 2007 May;23(3):310-6. Review.

PMID:
17414848
20.

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M.

Gastroenterology. 2006 Feb;130(2):465-81.

PMID:
16472600

Supplemental Content

Loading ...
Support Center